Latest Equities News

Imperial Pacific Limited reports a $652,000 net gain for the half year ending December 31, 2024, driven by strong investment performance and an increased dividend, despite ongoing challenges with its Excelsior Capital stake.

London City Equities Limited reports a robust 12% increase in its investment portfolio for the half year ending December 2024, driven by strong Fiducian Group performance and strategic share sales, enabling higher dividend payouts despite ongoing legal challenges.

Argosy Minerals Limited reported a net cash outflow in its December 2024 quarter, driven by exploration and evaluation expenses, ending with nearly $6 million in cash reserves.

Sagalio Energy Limited reported a net cash outflow of USD 79,000 in Q4 2024, ending the quarter with only USD 42,000 in cash and limited financing facilities. The company’s funding runway now stands at just over two quarters, raising questions about its near-term financial strategy.

Oneview Healthcare reported a robust Q4 2024 cash flow update, bolstered by a significant equity raise and expanding partnerships, positioning the company for accelerated growth in 2025.

ENRG Elements Limited reported a $586,000 net cash outflow for the December quarter, offset by a $2.02 million equity raise, boosting its cash reserves to $2.52 million.

Kalamazoo Resources Limited reported a $449,000 net cash outflow from operating activities in Q2 2024, maintaining a cautious stance as it explores funding options to sustain its exploration efforts.

Arafura Rare Earths Limited has acknowledged a breach of ASX Listing Rule 15.7 following premature media disclosure of a $200 million investment commitment from the National Reconstruction Fund Corporation. The company outlines corrective steps to prevent future compliance lapses.

Entyr Limited has launched a $9.5 million capital raising via a Share Purchase Plan and Placement Offer, aiming to recapitalize and return to ASX trading following its recent voluntary administration.

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.

Clime Investment Management has reported a return to profitability in the December half, proposing an interim dividend and unveiling strategic initiatives to drive future growth.

BOD Science has executed an asset sale deed transferring critical intellectual property rights to Optimus Salvus, marking a pivotal step in its Deed of Company Arrangement process.